Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

BACKGROUND: Despite the advancements in new therapies for colorectal cancer (CRC), chemotherapy still constitutes the mainstay of the medical treatment. For this reason, new strategies to increase the efficacy of chemotherapy are desirable. Poly-ADP-Ribose Polymerase inhibitors (PARPi) have shown to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Exp Clin Cancer Res
Hauptverfasser: Vitiello, Pietro Paolo, Martini, Giulia, Mele, Luigi, Giunta, Emilio Francesco, De Falco, Vincenzo, Ciardiello, Davide, Belli, Valentina, Cardone, Claudia, Matrone, Nunzia, Poliero, Luca, Tirino, Virginia, Napolitano, Stefania, Della Corte, Carminia, Selvaggi, Francesco, Papaccio, Gianpaolo, Troiani, Teresa, Morgillo, Floriana, Desiderio, Vincenzo, Ciardiello, Fortunato, Martinelli, Erika
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2021
Schlagworte:
Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7789007/
https://ncbi.nlm.nih.gov/pubmed/33407715
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-020-01811-8
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge